Variant position: 393 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 437 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human RLSP---------------LVAADSLLEHVREDFS GLLPEE--FISLSPPHEALDYHF
Mouse QLSP---------------LVAADSLLEHVKEDFS GLLPGE
Rat RLSP---------------LVAADSLLEHVKEDFS GLLPGE
Chicken SLSP---------------LASMDTLLEHGKDDFP GFLADE
Drosophila SLPPGVADCDANSNSSSVTLQGLDALFNDIGSDY- --FSND
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 437 Transcription factor E2F1
368 – 437 Transactivation
375 – 375 Phosphoserine
403 – 403 Phosphoserine; by GSK3-beta
403 – 403 S -> A. Decreased phosphorylation by GSK3B, leading to abolished interaction with USP11 and subsequent deubiquitination.
411 – 411 Y -> C. No retinoblastoma protein binding. No effect on interaction with and repression of CEBPA.
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS HIS-252; MET-276; ASN-311 AND SER-393;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.